Quarterly Results

202601 Results Summary

Revenue

The revenue stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

Operating Profit

Operating Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

PBDT

PBDT stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

Profit Before Tax

Profit Before Tax stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

Net Profit

Net Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This represents a per cent year-on-year *(YoY) decline for the same year.

  • YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.

Company News

More

Earnings

CategoryQ2 FY25-26Q2 FY24-25Change %FY24-25FY23-24Change %
Total Revenue14,478.3113,291.398.9352,578.4448,496.858.42
Expenses9,951.269,352.436.4037,984.6035,968.045.61
Other Income469.92354.0032.751,965.041,354.1945.11
Operating Profit569.78423.1734.6516,558.8813,883.0019.27
Depreciation729.50625.9116.552,575.392,556.640.73
Interest99.8669.1744.37231.36238.47-2.98
Profit Before Tax4,155.473,604.5415.2813,752.1311,087.8924.03
Tax1,030.52567.2181.682,772.031,439.4592.58
Net Profit3,117.953,040.162.5610,980.109,648.4413.80
CategoryQ2 FY25-26Q1 FY25-26Change %
Total Revenue14,478.3113,851.404.53
Expenses9,951.2610,367.74-4.02
Other Income469.92464.461.18
Operating Profit569.78539.265.66
Depreciation729.50700.554.13
Interest99.8674.8033.50
Profit Before Tax4,155.473,163.0231.38
Tax1,030.52870.1518.43
Net Profit3,117.953,096.630.69

Research Reports

ActionTarget Price (₹)BrokerDateReports
Data Not Found

Financial Reports

Data not available.

Stock Prices Compare with Peers

Company1 Day1 Week1 Month3 Months6 Month1 Year
Data Not Found

Corporate Information

Company News

Sun Pharma launches blockbuster plaque psoriasis drug Ilumya in India

Ilumya, a novel biologic treatment that selectively inhibits IL-23, has already established itself as a blockbuster drug internationally, with presence across 35 countries

Updated On: 01 Dec 2025 | 11:30 AM IST

Sun Pharma sees Golden Cross; other pharma stocks with similar pattern

Technically, the term 'Golden Cross' has bullish implications with short-term support seen moving higher. Apart from Sun Pharma, Aurobindo Pharma and Divi's Labs too witnessed this formation recently.

Updated On: 26 Nov 2025 | 10:57 AM IST

Will Nifty scale new highs soon? Analyst decodes with three stock picks

Stocks to buy: Ajit Mishra of Religare Broking recommends buying Bank of Baroda, Coforge, and Sun Pharma; also suggests Nifty trading strategy

Updated On: 20 Nov 2025 | 7:35 AM IST

AstraZeneca, Sun Pharma sign deal to distribute hyperkalaemia drug in India

AstraZeneca Pharma India and Sun Pharmaceutical Industries have formed an exclusive brand partnership to promote and distribute SZC for hyperkalaemia treatment under separate brands

Updated On: 18 Nov 2025 | 1:49 PM IST

Innovative portfolio likely to maintain growth momentum for Sun Pharma

Specialty portfolio powers Q2; Ilumya, Leqselvi, Unloxcyt to anchor next phase

Updated On: 06 Nov 2025 | 6:42 PM IST

Sun Pharma Q2 net profit rises 2.5% to ₹3,118 crore on India, EM growth

Sun Pharma's Q2FY26 profit rose to Rs 3,118 crore as India, emerging markets, and rest of world drove growth; US revenues fell 4.1% despite strong gains in innovative medicines

Updated On: 05 Nov 2025 | 5:49 PM IST

Sun Pharma Q2 preview: Profit may dip YoY despite revenue growth; details

Sun Pharma's net profit is expected to come at ₹2,843.4 crore, marking an average decline of 3 per cent Y-o-Y, as against ₹2,932.3 crore in the year-ago period

Updated On: 04 Nov 2025 | 12:42 PM IST

Stocks to buy today: Analyst bets on Sun Pharma, Indus Towers; check why

Shrikant Chouhan, Head of Equity Research at Kotak Securities, has recommended buying shares of Sun Pharma and Indus Towers today

Updated On: 28 Oct 2025 | 7:28 AM IST

Churning portfolio ahead of Diwali? Ambit lists top 10 'winning' stocks

Ambit analysts see HDFC Bank benefiting from accelerating credit growth, normalisation in cost of funds, and focus on high-yield segments like MSME, gold, and unsecured retail loans.

Updated On: 09 Oct 2025 | 11:20 AM IST

Lupin, Granules: Which pharma stocks to buy, sell amid US tariff flip-flop?

Technical charts show that select pharma stocks are trading with a negative bias and can tumble up to 19% from here. Granules India, however, looks strong on chart and can rally up to 19%.

Updated On: 09 Oct 2025 | 11:24 AM IST
More